BioAge Labs (BIOA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.58
- Estimate
- -$0.62
- Surprise
- +7.1%
- Revenue (period 2026-06-30)
- $2.5M
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
BioAge Labs (BIOA) reported a narrower loss than forecast — adjusted EPS of -$0.58 against the -$0.62 estimate (a 7.1% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates BIOA Hold at 4.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +7.1% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $35.62 vs price $6.29 — ratio 5.7×). Rejected, falling back to technical TP.
- Market cap $289M below $400M minimum
- Momentum score 3.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.29
- Price target
- $9.21
- Stop
- $5.85
- Upside to target
- +46.4%
Risk check: RSI 27 — a level conventionally read as oversold; trading volume is running 3.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
BIOA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $288.7M
- P/E (fwd)
- -2.6
- 52-week range
- $5.04–$25.95
- Off 52-week high
- 75.8%
- RSI (14)
- 27
- Volume vs avg
- 3.69×
- Score today
- 4.3/10